Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated Feb. 1, 2023:
Effective March 1, 2023:
- Camzyos
- Long Acting Insulin
- HEMLIBRA
- Human Fibrinogen Concentrate
- IL-4 Inhibitor
- IL-5 Inhibitors
- Lysosomal Storage Disorders
- Relyvrio
- Spevigo
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.